China corruption watchdog eyes CFDA, health ministry

China flag
China flag

Bribery remains a pressing issue for drug purchases through China's health ministry and regulatory enforcement by the China FDA shows repeated loopholes, the country's anticorruption watchdog has said.

Reuters reported that the Central Commission for Discipline Inspection (CCDI), run by Chinese Communist Party leadership, posted the observations on its website--often a prelude to enforcement action.

The CCDI said inspections of the two bodies responsible for much of the nation's healthcare policies at state-run hospitals and for drug approvals found the bribery and regulatory lapses. Senior bureaucrats at both agencies have now vowed to tackle the problems.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

The notices came shortly after China's National Development and Reform Commission (NDRC) announced an investigation into all aspects of drug and medical device sales and prices among domestic and foreign firms.

The regulatory loopholes likely reference a scandal earlier this year that saw a mother-and-daughter team in Shandong province act as wholesalers for vaccine sales without following proper storage and expiry monitoring protocols for a 5-year period.

The incident sparked outrage among parents and embarrassed top leadership who have vowed to crack down on adulterated and poor-quality food and drug products as part of a broader campaign against official corruption led by President Xi Jinping.

China has also taken recent steps to curb rising drug prices by eliminating a 15% markup at 200 state-run hospitals among other steps to centralize purchases now spread among institutions and provincial governments.

- here's the story from Reuters
- here's the CCDI website


Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.